Surgical resection and liver transplantation are the only curative therapies for hepatocellular carcinoma (HCC); however, fewer than 20% of patients are eligible for these therapies.1 Surgical resection is the treatment of choice for HCC in patients with a solitary tumor and no evidence of cirrhosis; this disease pattern accounts for roughly 5% of HCC in western countries and 40% in Asia.1 The higher percentage of HCC patients in Asia who are amenable to surgical resection is related to the predominance of hepatitis B virus (HBV)–related HCC, which can occur in the absence of cirrhosis. Improvement in early diagnosis of HCC and more accurate evaluation of underlying liver function have resulted in 5-year survival after resection for HCC exceeding 50%.1 Nevertheless, despite careful selection, HCC recurrence rate after surgical resection is high: 50% to 70% at 5 years.1 None of the adjuvant therapies prior to or immediately following resection have been shown to reduce the rate of HCC recurrence.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.